Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PAK3 | O75914 | 2/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.31 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 3/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672437 | 0.80 | BRD4 (0.38) | APPSCN10AMEN1POLBMAPK1 | |
| SCHEMBL13604903 | 0.78 | CYP3A4 (0.33) | APPSCN10AMEN1POLBMAPK1 | |
| SCHEMBL21672428 | 0.77 | AHR (0.35) | APPSCN10ACYP3A4AHRCMA1 | |
| SCHEMBL16982068 | 0.75 | FEN1 (0.36) | — | |
| SCHEMBL14602870 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL22792660 | 0.70 | GPR84 (0.40) | MEN1POLBMAPK1KMT2ACYP3A4 | |
| SCHEMBL21743424 | 0.68 | BRD4 (0.37) | APPMEN1POLBMAPK1KMT2A | |
| SCHEMBL19367490 | 0.68 | PDPK1 (0.33) | — | |
| SCHEMBL13604898 | 0.68 | DYRK1A (0.33) | — | |
| SCHEMBL8957480 | 0.67 | GPR84 (0.48) | MEN1POLBMAPK1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | APP 3561/4885SCN10A 1747/4885MEN1 2858/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | APP 3611/4885SCN10A 1766/4885MEN1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.